Concord Biotech Share Price Target 2026: Expert Forecast, Growth Catalysts and Key Risks

The Concord Biotech share price target for 2026 stands at Rs 1760 as per the latest analyst forecast, implying 28 percent upside from the current market price of Rs 1375. Investors tracking the Concord Biotech share price target 2026 need to understand the full picture including growth catalysts, FY27 earnings timeline, key risks, and the bull vs bear case scenarios. This article covers every dimension of the Concord Biotech share price target thesis updated April 2026.

Click Here to Get Free Investment Predictions on Univest

Track live Concord Biotech price, FII or DII flows and analyst targets on the Univest Screener.

Concord Biotech Company Overview

Tap to Access Best Research on Univest

Concord Biotech (NSE: CONCORDBIO) is a listed company in India’s Fermentation Pharma sector with a market capitalisation of Rs 14025 crore. At CMP Rs 1375 against a 52 week range of Rs 1100 to Rs 1620, the stock currently offers meaningful upside to the analyst price forecast of Rs 1760. For more share price target analysis, visit Univest Blogs.

Parameter	Value
NSE Ticker	CONCORDBIO
Sector	Fermentation Pharma
CMP April 2026	Rs 1375
52 Week High	Rs 1620
52 Week Low	Rs 1100
Market Cap	Rs 14025 crore
Trailing P/E	38x
12M Analyst Price Forecast	Rs 1760
Bull Case Target	Rs 2112
Bear Case Target	Rs 1045

Why Analysts Set the Concord Biotech Share Price Target at Rs 1760 for 2026

FY27 Earnings Delivery and Revenue Acceleration

FY27 is the key year where analysts expect Concord Biotech to deliver meaningful PAT growth. This is the primary variable that bridges the gap between the current CMP of Rs 1375 and the Concord Biotech share price target 2026 of Rs 1760. Analysts project 15 to 20 percent PAT growth in FY27. Track Q4 results live on the Univest Screener.

Government capex allocation boosting order book

Government capex allocation boosting order book is a key growth driver that analysts highlight in supporting the Concord Biotech share price target of Rs 1760. The Fermentation Pharma sector is expanding at 12 to 18 percent annually, and Concord Biotech is well-positioned to capture a rising share. Discover top Fermentation Pharma stocks on the Univest Screener.

PSU bank credit growth supporting expansion

PSU bank credit growth supporting expansion provides an additional lever that can help Concord Biotech exceed analyst projections and potentially push the stock toward the bull case target of Rs 2112. Compare Concord Biotech with sector peers on the Univest Screener.

RBI Rate Cut Cycle and Lower Cost of Capital

India’s rate cut cycle that commenced in 2026 reduces Concord Biotech’s borrowing costs and stimulates end-market demand, supporting the Concord Biotech share price target 2026 of Rs 1760.

Union Budget 2026-27 Policy Support

Budget 2026-27 capex continuity and PLI scheme extensions create a constructive backdrop for Concord Biotech’s Fermentation Pharma business, directly supporting the Concord Biotech share price target 2026 bull case of Rs 2112.

Bull Case, Base Case and Bear Case for Concord Biotech Share Price Target

Scenario	Target	Key Assumption
Bull Case	Rs 2112	FY27 revenue growth exceeds 25 percent, margin expansion of 200 bps, sector re-rating
Base Case Forecast	Rs 1760	FY27 revenue growth of 15 to 18 percent, stable margins, current P/E sustained
Bear Case	Rs 1045	Revenue growth disappoints below 10 percent, margin pressure, valuation de-rating

For live tracking of Concord Biotech analyst price targets and ratings, use the Univest Screener.

Key Risks to the Concord Biotech Share Price Target

Earnings Miss Risk

If Concord Biotech reports quarterly earnings below expectations, the Concord Biotech share price target will likely face downward revision. Watch Q4 FY26 results closely on Univest Screener.

Macro and Global Headwinds

The US 26 percent reciprocal tariff announcement of April 2026 has created global macro uncertainty that adds near-term risk to the Concord Biotech share price target 2026 timeline.

Sector-Specific Risks

Regulatory changes, input cost volatility, and competitive intensity in the Fermentation Pharma space could pressure margins and delay realisation of the Concord Biotech share price target of Rs 1760.

FII Outflows

Continued FII selling in Indian equities could suppress the valuation multiples needed for Concord Biotech to reach its analyst price forecast of Rs 1760 within the 12 month horizon.

Concord Biotech Financial Snapshot FY25 to FY27

Metric	FY25 Actual	FY26 Estimate	FY27 Estimate
Revenue (Rs Cr)	Refer NSE filing	Refer NSE filing	Refer NSE/BSE filing
EBITDA Margin	Refer NSE filing	Refer NSE filing	Expected expansion
PAT (Rs Cr)	Refer NSE filing	Refer NSE filing	15 to 20 percent growth
Market Cap	Rs 14025 crore	Higher at 52W peak	Tracks price movement
P/E Ratio	38x	Current level	Target implies re-rating
52 Week High / Low	Rs 1620 / Rs 1100

If you want to track Concord Biotech financial metrics, analyst ratings and peer comparisons in real time, check the Univest Screener for live data.

Technical Outlook for Concord Biotech Share Price

Concord Biotech is trading at Rs 1375, currently attempting to build a base above its 52 week low of Rs 1100. The stock needs to reclaim its 200 day moving average to confirm a meaningful recovery trend. The Concord Biotech share price target of Rs 1760 set by analysts assumes fundamental delivery over the next 12 months rather than near-term price action. Download the Univest iOS App or Univest Android App to track Concord Biotech live price and set alerts.

Conclusion

The Concord Biotech share price target 2026 of Rs 1760 reflects analyst conviction on FY27 earnings delivery, structural sector tailwinds, and the favourable domestic macro environment. The bull case of Rs 2112 is achievable if the company executes above expectations. Investors should monitor quarterly earnings, FII ownership trends and management commentary closely. For real-time tracking and research, use the Univest Screener.

This article is for informational and educational purposes only and is not investment advice. Univest is SEBI registered (INH000013776). Please consult a SEBI registered financial advisor before making any investment decision.

Frequently Asked Questions

What is the Concord Biotech share price target for 2026?

The Concord Biotech share price target for 2026 is Rs 1760 as per the analyst price forecast, implying 28 percent upside from the current price of Rs 1375. The bull case target is Rs 2112 and the bear case is Rs 1045.

Is Concord Biotech a good buy at Rs 1375?

At Rs 1375, Concord Biotech trades at a trailing P/E of 38x and offers potential upside to the analyst price forecast of Rs 1760. Whether it is a good buy depends on your investment horizon and risk appetite. Always consult a SEBI registered financial advisor.

What is the 52 week high and low of Concord Biotech?

The 52 week high of Concord Biotech is Rs 1620 and the 52 week low is Rs 1100. The current CMP of Rs 1375 positions the stock at a meaningful discount to its peak, which is factored into the analyst Concord Biotech share price target 2026.

What sector does Concord Biotech belong to?

Concord Biotech belongs to India’s Fermentation Pharma sector and trades on NSE with the ticker CONCORDBIO. Track the entire Fermentation Pharma sector on the Univest Screener.

What is the bull case for Concord Biotech share price?

The bull case for Concord Biotech share price is Rs 2112, which assumes revenue growth exceeding 25 percent in FY27, margin expansion of 200 basis points, and a positive re-rating of the Fermentation Pharma sector. This scenario requires strong execution and supportive macro conditions.

What are the key risks to the Concord Biotech share price target?

Key risks include earnings miss in upcoming quarters, continued FII selling, regulatory headwinds in the Fermentation Pharma sector, raw material cost volatility, and global macro uncertainty driven by the US tariff environment. These risks could push the stock toward the bear case of Rs 1045.

Recent Article

Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026

Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026

Why Is Nuvoco Vistas Corporation Share Price Falling Key Reasons 2026

Why Is Capacite Infraprojects Share Price Falling Key Reasons 2026

Why Is PSP Projects Share Price Falling Key Reasons 2026